[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA
[2] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
来源:
VIRUSES-BASEL
|
2011年
/
3卷
/
10期
基金:
美国国家卫生研究院;
关键词:
Dengue vaccine;
DNA vaccine;
vectored-vaccine;
sub-unit protein vaccine;
NEUTRALIZING ANTIBODY-RESPONSE;
GLYCOPROTEIN PROTECT MICE;
TETRAVALENT DNA VACCINE;
FLAVIVIRUS-NAIVE ADULTS;
VIRUS E-GLYCOPROTEIN;
IMMUNE-RESPONSES;
MONOCLONAL-ANTIBODIES;
NONHUMAN-PRIMATES;
ADENOVIRUS VECTOR;
SUBUNIT VACCINE;
D O I:
10.3390/v3101800
中图分类号:
Q93 [微生物学];
学科分类号:
071005 ;
100705 ;
摘要:
Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.